Fundraising FoxCatalio Capital Management, LP — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsForesite CapitalGeneral CatalystHBM Healthcare InvestmentsHBM PartnersHongShan Capital GroupLAV+4 more
.png)
Elektrofi is a biotech company developing an ultra-high concentration microparticle formulation platform that enables subcutaneous delivery of biologic medicines such as monoclonal antibodies.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Sam Huang(Director)Chase Coffman(Chief Executive Officer & Co-founder)Jason Norris(Co-founder)Charles L. Cooney(Director)Andrew Goldberg(Director)Constatine Chinoporos(Director)
Co-investorsBiotechnology Value FundNovo HoldingsCharlotte Angel FundGeneral CatalystRA CapitalSR One Capital Management+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.